Stock analysts expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) to report sales of $166.35 million for the current fiscal quarter, according to Zacks. Two analysts provided earnings estimates for Supernus Pharmaceuticals. The lowest sales estimate is $165.39 million and the highest is $167.30 million. Supernus Pharmaceuticals recorded sales of $141.33 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 17.7%. The company is expected to announce its next earnings report on Monday, January 1.
According to Zacks, analysts expect Supernus Pharmaceuticals to post annual revenue of $675.35 million for the current fiscal year, with estimates ranging from $671.30 to $679.39 million. For next year, analysts expect the company to post sales of $613.91 million, with estimates ranging from $603.85 million to $629.18 million. Zacks sales calculations are an average based on a survey of sell-side research analysts who track Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last reported quarterly results on Monday, May 9. The specialty pharmaceutical company reported earnings per share (EPS) of $0.43 for the quarter, beating consensus analyst estimates of $0.26 by $0.17. The company posted revenue of $152.50 million in the quarter, versus a consensus estimate of $150.47 million. Supernus Pharmaceuticals had a return on equity of 9.05% and a net margin of 12.20%. The company’s revenue for the quarter increased 16.5% year over year. In the same quarter last year, the company posted EPS of $0.11.
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
SUPN has been the subject of several analyst reports. TheStreet downgraded Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a Monday, April 18 research report. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a Wednesday, May 11 research report. Finally, StockNews.com upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a Monday, April 18 research report.
A number of institutional investors have recently bought and sold shares of the company. Walleye Capital LLC acquired a new stake in Supernus Pharmaceuticals in the first quarter valued at $1,637,000. Keeley Teton Advisors LLC acquired a new stake in Supernus Pharmaceuticals in the first quarter valued at $356,000. Lido Advisors LLC acquired a new stake in Supernus Pharmaceuticals in the first quarter valued at $395,000. Eqis Capital Management Inc. acquired a new stake in Supernus Pharmaceuticals in the first quarter worth $200,000. Finally, Goldman Sachs Group Inc. increased its stake in Supernus Pharmaceuticals by 108.1% in the first quarter. Goldman Sachs Group Inc. now owns 550,081 shares of the specialty pharmaceutical company valued at $17,779,000 after buying an additional 285,737 shares last quarter.
Shares of Supernus Pharmaceuticals opened at $28.40 on Friday. Supernus Pharmaceuticals has a 1-year low of $23.15 and a 1-year high of $34.50. The company has a debt ratio of 0.48, a current ratio of 2.00 and a quick ratio of 1.69. The stock has a market capitalization of $1.52 billion, a P/E ratio of 21.85 and a beta of 1.12. The company’s 50-day simple moving average is $29.63 and its two-hundred-day simple moving average is $30.27.
Supernus Pharmaceuticals Company Profile (Get an evaluation)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, is focused on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended-release topiramate indicated for the treatment of epilepsy, as well as for the prophylaxis of migraines; and Oxtellar XR, an extended-release oxcarbazepine for the monotherapy treatment of partial-onset seizures in adults and children aged 6 to 17 years.
Featured Articles
Get a Free Copy of Zacks’ Research Report on Supernus Pharmaceuticals (SUPN)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Supernus Pharmaceuticals right now?
Before you consider Supernus Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Supernus Pharmaceuticals was not on the list.
Although Supernus Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here
